<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Gensight Biologics Sa — News on 6ix</title>
    <link>https://6ix.com/company/gensight-biologics-sa-1</link>
    <description>Latest news and press releases for Gensight Biologics Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 18:35:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/gensight-biologics-sa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d53790beedb30cb6f6f862.webp</url>
      <title>Gensight Biologics Sa</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1</link>
    </image>
    <item>
      <title>GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-annual-general-meeting-to-take-place-on-may-19-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-annual-general-meeting-to-take-place-on-may-19-2026-1</guid>
      <pubDate>Tue, 28 Apr 2026 18:35:00 GMT</pubDate>
      <description>PARIS, April 28, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 19, 2026, at 2:00 pm CEST at the Company’s headquarters at 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.</description>
    </item>
    <item>
      <title>GenSight Biologics Announces the Filing of its 2025 Universal Registration Document</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-filing-of-its-2025-universal-registration-document-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-filing-of-its-2025-universal-registration-document-1</guid>
      <pubDate>Wed, 15 Apr 2026 16:00:00 GMT</pubDate>
      <description>PARIS, April 15, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its 2025 Universal Registration Document (URD) in English was filed with the French market authority (Autorités des Marchés Financiers, or AMF) on April 14, 2026, under the reference D.26-0251.</description>
    </item>
    <item>
      <title>GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-reports-cash-position-and-revenue-from-early-access-program-as-of-march-31-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-reports-cash-position-and-revenue-from-early-access-program-as-of-march-31-2026-1</guid>
      <pubDate>Tue, 07 Apr 2026 16:59:00 GMT</pubDate>
      <description>PARIS, April 07, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026.</description>
    </item>
    <item>
      <title>GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-reports-estimated-full-year-consolidated-financial-results-for-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-reports-estimated-full-year-consolidated-financial-results-for-2025-1</guid>
      <pubDate>Fri, 27 Mar 2026 06:30:00 GMT</pubDate>
      <description>PARIS, March 27, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year consolidated financial results for 2025,1 as reviewed by the Audit Committee and the Board of Directors on March 25, 2026. The Board of Directors will approve the final accounts on Apr</description>
    </item>
    <item>
      <title>The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/the-15-20-national-hospital-and-gensight-biologics-announce-the-first-treatments-in-the-french-named-patient-early-access-program-aac-for-gs010lumevoqr-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/the-15-20-national-hospital-and-gensight-biologics-announce-the-first-treatments-in-the-french-named-patient-early-access-program-aac-for-gs010lumevoqr-1</guid>
      <pubDate>Fri, 20 Mar 2026 06:30:00 GMT</pubDate>
      <description>PARIS, March 20, 2026--Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the first patients have been treated in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®.1 The REVISE do</description>
    </item>
    <item>
      <title>GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-closing-of-its-nearly-euro17-million-fundraising-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-closing-of-its-nearly-euro17-million-fundraising-1</guid>
      <pubDate>Wed, 18 Mar 2026 09:15:00 GMT</pubDate>
      <description>PARIS, March 18, 2026--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA</description>
    </item>
    <item>
      <title>GenSight Biologics Announces Successful Fundraising Worth Nearly €1.7 Million</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-successful-fundraising-worth-nearly-euro17-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-successful-fundraising-worth-nearly-euro17-million-1</guid>
      <pubDate>Tue, 10 Mar 2026 08:00:00 GMT</pubDate>
      <description>PARIS, March 10, 2026--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA</description>
    </item>
    <item>
      <title>GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-provides-updates-about-gs010lumevoqr-early-access-programs-and-the-ongoing-revise-study-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-provides-updates-about-gs010lumevoqr-early-access-programs-and-the-ongoing-revise-study-1</guid>
      <pubDate>Mon, 09 Mar 2026 06:30:00 GMT</pubDate>
      <description>PARIS, March 09, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided updates on the GS010/LUMEVOQ® early access programs currently underway and the ongoing dose-ranging study REVISE. GS010/LUMEVOQ® is the Company’s candidate gene therapy in clinical development as a treatm</description>
    </item>
    <item>
      <title>GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-bolsters-regulatory-leadership-in-us-and-europe-with-two-senior-appointments-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-bolsters-regulatory-leadership-in-us-and-europe-with-two-senior-appointments-1</guid>
      <pubDate>Wed, 18 Feb 2026 06:30:00 GMT</pubDate>
      <description>PARIS, February 18, 2026--Regulatory News: GenSight Biologics (&quot;GenSight Biologics&quot; or the &quot;Company&quot;) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the strategic expansion of its Regulatory Affairs &amp; Quality department with two senior appointments following recent regulatory milestones.</description>
    </item>
    <item>
      <title>The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/the-15-20-national-hospital-and-gensight-biologics-announce-the-treatment-of-the-first-patient-in-the-gs010lumevoqr-revise-study-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/the-15-20-national-hospital-and-gensight-biologics-announce-the-treatment-of-the-first-patient-in-the-gs010lumevoqr-revise-study-1</guid>
      <pubDate>Tue, 10 Feb 2026 06:30:00 GMT</pubDate>
      <description>PARIS, February 10, 2026--Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the treatment of the first patient enrolled in the REVISE dose-ranging study. The open-label, single center study aims to enroll</description>
    </item>
    <item>
      <title>GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-results-of-its-extraordinary-general-meeting-of-january-28-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-results-of-its-extraordinary-general-meeting-of-january-28-2026-1</guid>
      <pubDate>Wed, 28 Jan 2026 23:21:00 GMT</pubDate>
      <description>PARIS, January 28, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its Extraordinary General Meeting held today at 3:00 p.m. approved all resolutions submitted to shareholders, with the exception of the 8th resolution relating to a reserved capital increase, which was</description>
    </item>
    <item>
      <title>GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-reports-cash-position-as-of-december-31-2025-and-provides-business-updates-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-reports-cash-position-as-of-december-31-2025-and-provides-business-updates-1</guid>
      <pubDate>Thu, 08 Jan 2026 17:00:00 GMT</pubDate>
      <description>PARIS, January 08, 2026--Regulatory News: GenSight Biologics (&quot;GenSight Biologics&quot; or the &quot;Company&quot;) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2025, and provided business updates.</description>
    </item>
    <item>
      <title>GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2.9 Million</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-closing-of-fundraising-worth-nearly-eur-29-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-closing-of-fundraising-worth-nearly-eur-29-million-1</guid>
      <pubDate>Wed, 07 Jan 2026 17:00:00 GMT</pubDate>
      <description>PARIS, January 07, 2026--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA</description>
    </item>
    <item>
      <title>GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2.9 Million</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-successful-fundraising-amounting-to-nearly-euro29-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-successful-fundraising-amounting-to-nearly-euro29-million-1</guid>
      <pubDate>Mon, 29 Dec 2025 07:00:00 GMT</pubDate>
      <description>PARIS, December 29, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA</description>
    </item>
    <item>
      <title>GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-regulatory-authorization-for-early-access-treatment-with-gs010lumevoqr-in-israel-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-regulatory-authorization-for-early-access-treatment-with-gs010lumevoqr-in-israel-1</guid>
      <pubDate>Mon, 22 Dec 2025 17:00:00 GMT</pubDate>
      <description>PARIS, December 22, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that Israel’s Ministry of Health Pharmaceutical Division has authorized the use of the candidate gene therapy GS010/LUMEVOQ®1 for the early access treatment of individual patients in the country.</description>
    </item>
    <item>
      <title>GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-granting-of-compassionate-use-authorization-cuaaac-for-gs010lumevoqr-in-france-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-the-granting-of-compassionate-use-authorization-cuaaac-for-gs010lumevoqr-in-france-1</guid>
      <pubDate>Mon, 22 Dec 2025 06:00:00 GMT</pubDate>
      <description>PARIS, December 22, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has granted compassionate use authorization (Autorisation d’Accès Compassionnel, or A</description>
    </item>
    <item>
      <title>GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-regulatory-approval-for-gs010lumevoqr-revise-dose-ranging-study-in-france-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-regulatory-approval-for-gs010lumevoqr-revise-dose-ranging-study-in-france-1</guid>
      <pubDate>Tue, 02 Dec 2025 16:43:00 GMT</pubDate>
      <description>PARIS, December 02, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has authorized the dose-ranging study REVISE, which will investigate the efficacy and</description>
    </item>
    <item>
      <title>Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/inherited-retinal-disease-market-analysis-report-2025-2035-featuring-profiles-of-novartis-gensight-biologics-aldeyra-therapeutics-and-spark-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/inherited-retinal-disease-market-analysis-report-2025-2035-featuring-profiles-of-novartis-gensight-biologics-aldeyra-therapeutics-and-spark-therapeutics</guid>
      <pubDate>Wed, 19 Nov 2025 14:05:00 GMT</pubDate>
      <description>The global inherited retinal disease market is poised for significant growth by 2025, driven by increasing prevalence of retinal conditions and advancements in genetic and cell-based therapies. Key diseases include retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease, which lead to progressive vision loss. Gene therapies and stem cell treatments are transforming the market alongside precision medicine advancements. While cost remains a barrier, emerging markets and regenerativ</description>
    </item>
    <item>
      <title>GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-closing-of-fundraising-worth-nearly-eur-2-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-closing-of-fundraising-worth-nearly-eur-2-million-1</guid>
      <pubDate>Thu, 13 Nov 2025 17:00:00 GMT</pubDate>
      <description>PARIS, November 13, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA</description>
    </item>
    <item>
      <title>GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2 Million</title>
      <link>https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-successful-fundraising-amounting-to-nearly-euro2-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gensight-biologics-sa-1/news/gensight-biologics-announces-successful-fundraising-amounting-to-nearly-euro2-million-1</guid>
      <pubDate>Mon, 10 Nov 2025 07:00:00 GMT</pubDate>
      <description>PARIS, November 10, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA</description>
    </item>
  </channel>
</rss>